Nomogram predicting survival of hepatocellular carcinoma with portal vein tumour thrombus after curative resection

2018 ◽  
Vol 89 (1-2) ◽  
pp. E20-E25 ◽  
Author(s):  
Yiren Hu ◽  
Sunwu You ◽  
Zhangwei Yang ◽  
Shuqun Cheng
Keyword(s):  
Hepatocellular Carcinoma ◽  
Portal Vein ◽  
Curative Resection ◽  
Tumour Thrombus ◽  
Portal Vein Tumour Thrombus

scholarly journals Portal Vein Stenting Combined with 125I Particle Chain Implantation Followed by As2O3 in the Treatment of Hepatocellular Carcinoma with Portal Vein Tumour Thrombus

2020 ◽  
Vol 2020 ◽  
pp. 1-7 ◽  
Author(s):  
Zhaonan Li ◽  
Guangyan Si ◽  
De-Chao Jiao ◽  
Xinwei Han ◽  
Wenguang Zhang ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Adverse Events ◽  
Portal Vein ◽  
Interventional Treatment ◽  
Treatment Needs ◽  
Stent Patency ◽  
Cumulative Survival ◽  
Tumour Thrombus ◽  
Particle Chain ◽  
Portal Vein Tumour Thrombus

Objective. To evaluate the feasibility and safety of portal vein stenting (PVS) combined with 125I particle chain implantation and sequential arsenic trioxide (As2O3) for the treatment of hepatocellular carcinoma (HCC) with portal vein tumour thrombus (PVTT) by transcatheter arterial chemoembolization (TACE). Methods. From January 2015 to January 2018, the clinical data of 30 patients with HCC complicated by PVTT were retrospectively analysed (26 men and 4 women). The laboratory examinations, incidence of adverse events, cumulative survival rate, and stent patency were analysed for all enrolled patients. Results. The success rate of interventional treatment in all patients was 100%. The results of the laboratory tests before and 1 week after surgery showed that the mean concentrations of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) decreased from 50.9 U/L ± 25.8 to 41.8 U/L ± 21.6 (P<0.001) and 57.6 U/L ± 19.9 to 44.2 U/L ± 26.1 (P<0.001), respectively. No complications in grade 3 or higher according to the Common Terminology Criteria for Adverse Events (CTCAE) were observed. The cumulative survival rates at 3, 6, 9, and 12 months were 83.1%, 69.2%, 43.7%, and 31.2%, respectively, while the patency rates of the stents were 83.3%, 80.0%, 52.2%, and 38.3%, respectively. Of the 30 deaths during the follow-up period, 16 patients died of liver failure, 8 died of gastrointestinal bleeding, 3 died of lung metastasis, 2 died of brain metastases, and 1 died of heart failure because the tumour invaded the atria. Conclusion. PVS combined with 125I particle chain implantation followed by TACE with As2O3 is safe and feasible for patients with PVTT. The long-term efficacy of this treatment needs to be further studied.

Transarterial chemoembolization of hepatocellular carcinoma with segmental portal vein tumour thrombus

2016 ◽  
Vol 27 (4) ◽  
pp. 1448-1458 ◽  
Author(s):  
Jin Woo Choi ◽  
Hyo-Cheol Kim ◽  
Jeong-Hoon Lee ◽  
Su Jong Yu ◽  
Yoon Jun Kim ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Portal Vein ◽  
Transarterial Chemoembolization ◽  
Tumour Thrombus ◽  
Portal Vein Tumour Thrombus

scholarly journals Combination treatment for advanced hepatocellular carcinoma with portal vein tumour thrombus: A case report

2021 ◽  
Vol 49 (2) ◽  
pp. 030006052199440
Author(s):  
Jianrong Wang ◽  
Junxue Wang ◽  
Jianzhu Wang ◽  
Ziliang Qian ◽  
Wensheng Xu ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Portal Vein ◽  
Combination Treatment ◽  
Good Health ◽  
Advanced Hepatocellular Carcinoma ◽  
Tumour Thrombus ◽  
Abdominal Magnetic Resonance Imaging ◽  
Portal Vein Tumour Thrombus ◽  
Magnetic Resonance Imaging Mri ◽  
Circulating Tumour Dna

We present a case of a 43-year-old man with advanced hepatocellular carcinoma (HCC) with portal vein tumour thrombus. Initially, transcatheter arterial chemoembolization (TACE) was performed. Although alpha-fetoprotein (AFP) levels decreased, circulating tumour DNA (ctDNA) levels showed an upward trend, and abdominal magnetic resonance imaging (MRI) showed that tumours in the portal vein had increased. Based on ctDNA profiling, apatinib and anti-programmed cell death protein 1 (anti-PD-1) antibodies and were sequentially administered. Approximately three months later, intrahepatic tumours had significantly diminished and AFP and ctDNA levels had reduced. The response was sustained at the 23-month follow-up and the patient was in good health. Combination treatment of TACE, apatinib and anti-PD-1 antibodies was effective, and profiling of ctDNA fragmentation may be beneficial in the therapeutic management of patients with HCC.

scholarly journals Conversion hepatectomy for hepatocellular carcinoma with main portal vein tumour thrombus after lenvatinib treatment: A case report

2021 ◽  
Vol 13 (3) ◽  
pp. 384-392
Author(s):  
Kazuhiro Takahashi ◽  
Jaejeong Kim ◽  
Amane Takahashi ◽  
Shinji Hashimoto ◽  
Manami Doi ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Case Report ◽  
Portal Vein ◽  
Main Portal Vein ◽  
Tumour Thrombus ◽  
Portal Vein Tumour Thrombus
Sign in / Sign up

Export Citation Format

Share Document